Vaccibody.com

August 12, 2015 Vaccibody AS announces approval to initiate its first clinical trial

Posted at 12:07h in Uncategorized

Vaccibody AS is pleased to announce that it has received the approval from the regulatory authorities (Paul Ehrlich Institute), of its clinical trial application for VB10.16 immunotherapy, the company’s lead drug candidate for the treatment high grade Cervical Intraepithelial Neoplasia (CIN 2/3) caused by human...

June 30, 2015 VACCIBODY APPOINTS MARTIN BONDE AS CEO

Posted at 14:28h in Uncategorized

The board of Vaccibody is pleased to announce Dr. Martin Bonde as the new CEO of the company from August 10th, 2015. Dr. Bonde has more than 25 years of international experience from the biotech industry. He started his career in Dako AS, followed by Ostemeter AS...

June 4, 2015 Vaccibody AS announces participation in a research project on veterinary vaccines receiving NOK 78 million from the EU Horizon 2020 program

Posted at 09:44h in Uncategorized

Vaccibody AS is pleased to announce initiation of a new 4 year collaborative research project with the aim to improve animal production and health through development of improved vaccination strategies. The SAPHIR project brings together interdisciplinary expertise from 14 academic institutions, 5 small and medium-sized...

May 26, 2015 Vaccibody aquaculture research collaboration receives NOK 10 million from the Norwegian Research Council

Posted at 08:34h in Uncategorized

The research collaboration “New Targeting Vaccines for Sustainable Aquaculture” has received a grant of NOK 10 Million through the Norwegian Research Council’s program Biotek2021. Vaccibody is a partner in the project together with The Norwegian Veterinary Institute, Pharmaq AS, Kjeller Innovasjon and Kongla AS. The...

February 23, 2015 Vaccibody AS announces filing of a Clinical Trial Application (CTA) to initiate the First in Man Clinical study of its lead Drug Candidate VB10.16

Posted at 12:44h in Uncategorized

Vaccibody AS, a biopharmaceutical company focusing on immunotherapy and vaccines, is pleased to announce the filing of a CTA to initiate the first in man clinical study of its lead drug candidate VB10.16. The CTA was filed with the Paul Ehrlich Institute, the Federal German...

January 27, 2015 Vacant position- Researcher/Engineer Vaccines/Immunotherapy

Posted at 12:45h in Uncategorized

Vaccibody is a vaccine company dedicated to the development of novel vaccines that overcome shortcomings of current vaccine technologies. The Company’s proprietary vaccine platform increases the antibody and T-cell responses leading to remarkably effective vaccines. Vaccibody plans to initiate its first clinical trial with a...

January 26, 2015 Vaccibody Granted Platform Patent in the US

Posted at 10:33h in Uncategorized

Vaccibody AS is pleased to announce that the U.S. Patent Office has Issued patent No. US 8,932,603 B2 covering the Vaccibody format which can be described as homodimeric modular constructs targeting vaccines to antigen presenting cells designed to increase the immune system’s antibody and T-cell...

December 3, 2014 Vaccibody Granted Platform Patent

Posted at 21:30h in Uncategorized

Vaccibody AS today announces that the European Patent Office (EPO) has granted European patent No. 1599504 covering the Vaccibody format which can be described as homodimeric modular constructs targeting vaccines to antigen presenting cells designed to increase the immune system’s antibody and T-cell responses. This patent...

October 31, 2014 Management change in Vaccibody AS

Posted at 16:58h in Uncategorized

As Vaccibody is entering into a new development phase, the Board of Directors has initiated a search process for a new CEO with experience from clinical development and strategic partnering. On this background, Ole Henrik Brekke, CEO since 2006, has decided to leave the...

July 1, 2014 Vaccibody successfully completes a 35 million NOK financing

Posted at 14:05h in Uncategorized

Vaccibody has in a new share issue completed a 35 MNOK (4.3 million €) financing from existing and new investors. The share issue was significantly oversubscribed. The largest new investor is represented by Datum and partners, which will take a seat in the Board of...